- Home
- BPMC vs CYTK Comparison
BPMC vs CYTK Comparison
Compare BPMC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- CYTK
- Stock Information
- Founded
- BPMC 2008
- CYTK 1997
- Country
- BPMC United States
- CYTK United States
- Employees
- BPMC N/A
- CYTK N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- BPMC Health Care
- CYTK Health Care
- Exchange
- BPMC Nasdaq
- CYTK Nasdaq
- Market Cap
- BPMC 5.8B
- CYTK 5.6B
- IPO Year
- BPMC 2015
- CYTK 2004
- Fundamental
- Price
- BPMC $128.20
- CYTK $32.43
- Analyst Decision
- BPMC Buy
- CYTK Buy
- Analyst Count
- BPMC 20
- CYTK 14
- Target Price
- BPMC $127.82
- CYTK $70.92
- AVG Volume (30 Days)
- BPMC 6.4M
- CYTK 1.3M
- Earning Date
- BPMC 07-31-2025
- CYTK 08-07-2025
- Dividend Yield
- BPMC N/A
- CYTK N/A
- EPS Growth
- BPMC N/A
- CYTK N/A
- EPS
- BPMC N/A
- CYTK N/A
- Revenue
- BPMC $562,121,000.00
- CYTK $19,218,000.00
- Revenue This Year
- BPMC $44.46
- CYTK $18.02
- Revenue Next Year
- BPMC $32.78
- CYTK $737.32
- P/E Ratio
- BPMC N/A
- CYTK N/A
- Revenue Growth
- BPMC 99.19
- CYTK 412.21
- 52 Week Low
- BPMC $73.04
- CYTK $29.31
- 52 Week High
- BPMC $128.34
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- BPMC 75.62
- CYTK 46.32
- Support Level
- BPMC $127.86
- CYTK $32.02
- Resistance Level
- BPMC $128.33
- CYTK $34.72
- Average True Range (ATR)
- BPMC 0.41
- CYTK 1.30
- MACD
- BPMC -0.32
- CYTK 0.26
- Stochastic Oscillator
- BPMC 84.62
- CYTK 45.08
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.